New lipoxygenase inhibitors of reactive oxygen species production in cellular models of Amyloid (A2) toxicities

Journal of Alzheimer's Disease

Volumn 34, Issue 1, 2013, Pages 215-230

  Pontiki, Eleni ^a,b   Kontogiorgis, Christos ^a,b   Xu, Yanan ^b   Hadjipavlou Litina, Dimitra ^a   Luo, Yuan ^b,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Amyloid peptide; aryl acetic acid derivatives; hydrogen peroxide scavengers; N2a neuroblastoma cells; .9 mutant cells

Indexed keywords

ARYLACETIC ACID DERIVATIVE; HYDROGEN PEROXIDE; LIPOXYGENASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL LINE; CELL PROTECTION; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; NERVE CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 84874305428     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-120940     Document Type: Article

References (81)

1. Markesbery WR, Lovell MA (2006) DNA oxidation in Alzheimer's disease. Antioxid Redox Signal 8, 2039-2045. (Pubitemid 46489629)
2. Markesbery WR, Lovell MA (2007) Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64, 954-956. (Pubitemid 47047994)
3. Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G (2008) Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 44, 1493-505.
4. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632. (Pubitemid 27120096)
5. Esiri MM (2007) The interplay between inflammation and neurodegeneration in CNS disease. J Neuroimmunol 184, 4-16. (Pubitemid 46365987)
6. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55.
7. McGeer PL, McGeer EG, Rogers J, Sibley J (1990) Antiinflammatory drugs and Alzheimer's disease. Lancet 335, 1037.
8. In t'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal anti-inflammatory drugs and risk of Alzheimer's disease. N Engl J Med 345, 1515-1521.
9. Ka MH, Choi EH, Chun HS, Lee KG (2005) Antioxidative activity of volatile extracts isolated from Angelica tenuissimae roots, Peppermint Leaves, Pine Needles and Sweet Flag Leaves. J Agric Food Chem 53, 4124-4129. (Pubitemid 40936773)
10. Molina-Jimenez MF, Sanchez-Reus MI, Andres D, Cascales M, Benedi J (2004) Neuroprotective effect of fraxetin and myricatin against rotenone-induced apoptosis in neuroblastoma cells. Brain Res 1009, 9-16. (Pubitemid 38553843)
11. Petersen RB, Nunomura A, Lee HG, Casadesus G, Perry G, Smith MA, Zhu X (2007) Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J Alzheimers Dis 11, 143-152. (Pubitemid 47010981)
12. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging 18, 685-716. (Pubitemid 32948277)
13. Montine K, Quinn J, Montine T (2003) Membrane lipid peroxidation. In Membrane Lipid Signaling in Aging and Age-Related Disease, Mattson M, ed. Elsevier, Amsterdam, pp. 11-26.
14. Labieniec M, Gabryelak T (2006) Study of interactions between phenolic compounds and H2O2 or Cu (II) ions in B14 Chinese hamster cells. Cell Biol Int 30, 761-768. (Pubitemid 44592640)
15. Lambeth JD (2004)NOXenzymes and the biology of reactive oxygen. Nat Rev Immunol 4, 181-189.
16. Butterfield DA (2003) Amyloid beta-peptide 1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: Mechanisms and consequences. Curr Med Chem 10, 2651-2659. (Pubitemid 37456035)
17. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502, 139-144. (Pubitemid 30433863)
18. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA (2001) Differential activation of neuronal ERK, NK/SAPK, p38 in Alzheimer disease: The 'two hit' hypothesis. Mech Ageing Dev 123, 39-46. (Pubitemid 32972257)
19. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X (2009) The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 109, 153-159.
20. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins ad therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
21. Poli G (2000) Molecular and cellular aspects of oxidative damage in Alzheimer's disease. In: Free Radicals in Brain Pathophysiology, Smith MA, Perry G, eds. Dekker M, Torino, pp. 313-321.
22. Yatin SM, Varadarajan S, Butterfield DA (2000) Vitamin E prevents Alzheimer's amyloid beta-peptide 1-42]-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2, 123-131.
23. Murrell J, Farlow M, Ghetti B, Benson M (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99. (Pubitemid 21917324)
24. Guo Q, Robinson N, Mattson MP (1998) Secreted β-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NFkB and stabilization of calcium homeostasis. J Biol Chem 273, 12341-12351. (Pubitemid 28240603)
25. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, VanMuiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
26. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G (1999) p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 72, 2053-2058. (Pubitemid 29186010)
27. Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, Perry G (2008) Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 7, 3-10. (Pubitemid 351516211)
28. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
29. Pratico D, Delanty N (2000) Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease. Am J Med 109, 577-585.
30. Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β-peptide (1-42). Neurobiol Aging 20, 325-330. (Pubitemid 29525418)
31. Pratico D (2004) Lipid peroxidation and oxidative imbalance: Early functional events in Alzheimer's disease. J Alzheimers Dis 6, 171-175. (Pubitemid 38560253)
32. Pratico D, Trojanowski JQ (2000) Inflammatory hypotheses: Novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol Aging 21, 441-445. (Pubitemid 30349112)
33. Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768, 1976-1990. (Pubitemid 47125850)
34. Sayre LM, Perry G, Harris PL, LiuY, Schubert KA, SmithMA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals. J Neurochem 74, 270-279. (Pubitemid 30012778)
35. Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study. Neurology 54, 2066-2071. (Pubitemid 30397203)
36. Morris MC, EvansDA, Bienias JL, Tangney CC, BennettDA, Aggarwal N, Wilson RS, Scherr PA (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287, 3230-3237. (Pubitemid 34686104)
37. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS (2002) Vitamin E and cognitive decline in older persons. Arch Neurol 59, 1125-1132. (Pubitemid 34755825)
38. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223-3229. (Pubitemid 34686103)
39. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, CotmanCW, Pfeiffer E, Schneider LS, Thal LJ (1997) controlled trial of selegiline, -tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222. (Pubitemid 27183651)
40. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65, 631-641. (Pubitemid 44297254)
41. Zandi PP, Anthony JC, Khachaturian AS, StoneSV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antiox idant vitamin supplements: The Cache County Study. Arch Neurol 61, 82-88. (Pubitemid 38067418)
42. Boothby LA, Doering PL (2005) Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 39, 2073-2080.
43. Olivieri G, Baysang G, Meier F, Müller-Spahn F, Stähelin HB, Brockhaus M, Brack Ch (2001) N-Acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: Effects on β-amyloid secretion and tau phosphorylation. J Neurochem 76, 224-233. (Pubitemid 32044386)
44. Smith JV, Luo Y (2003) Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Gingko biloba extract EGb 761. J Alzheimers Dis 5, 287-300. (Pubitemid 37411776)
45. Zhao B (2009) Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem Res 34, 630-638.
46. Zandi PP, Breitner JC (2001)DoNSAIDsprevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22, 811-817. (Pubitemid 34066547)
47. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386. (Pubitemid 23250354)
48. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T (2002) Cyclin D1 and cyclin E are colocalized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 61, 678-688. (Pubitemid 34851771)
49. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57, 295-303. (Pubitemid 29339785)
50. Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioural impairments in the rat. J Neurosci Res 68, 337-343. (Pubitemid 34462539)
51. Joseph JA, Shukitt-Halem B, Casadesus G, Fisher D (2005) Oxidative stress and inflammation in brain aging: Nutritional considerations. Neurochem Res 30, 927-935. (Pubitemid 41413949)
52. Chinnici CM, Yao Y, Pratico D (2007) The 5-lipoxygenase enzymatic pathway in the mouse brain: Young versus old. Neurobiol Aging 28, 1457-1462. (Pubitemid 47081230)
53. Manev H, Uz T, Sugaya K, Qu T (2000) Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J 14, 1464-1469. (Pubitemid 30439756)
54. Tomimoto H, Shibata M, Ihara M, Akiguchi I, Ohtani R, Budka H (2002) A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol 104, 601-607. (Pubitemid 36075425)
55. Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ (2006) Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology 26, 99-106.
56. Zhou Y, Wei EQ, Fang SH, Chu LS, Wang ML, Zhang WP, Yu GL, Ye YL, Lin SC, Chen Z (2006) Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci 79, 1645-1656. (Pubitemid 44349150)
57. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D (2008) 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 22, 1169-1178. (Pubitemid 351519971)
58. Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ, Lee VM (2004) 12/15-lipoxygenase is increased in Alzheimer's disease: Possible involvement in brain oxidative stress. Am J Pathol 164, 1655-1662. (Pubitemid 38529768)
59. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D (2005) Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58, 623-626. (Pubitemid 41377227)
60. Goodman Y, Steiner MR, Steiner SM, Mattson MP (1994) Nordihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res 654, 171-176. (Pubitemid 24259417)
61. Klegeris A, McGeer PL (2002) Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 23, 787-794. (Pubitemid 35217703)
62. Sugaya K, Uz T, Kumar V, Manev H (2000) New antiinflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 82, 85-94. (Pubitemid 30153588)
63. Chu J, Pratico D (2011) Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of β-secretase. Am J Pathol 178, 1762-1769.
64. Imbimbo BP, Solfrizzi V, Panza F (2010) Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Ageing Neurosci 19, 1-14.
65. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289, 2819-2826. (Pubitemid 37430117)
66. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM, Pratico D (2004) Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer disease. Am J Pathol 165, 2197-2206. (Pubitemid 39578396)
67. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611. (Pubitemid 23230557)
68. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib Protocol 091 Study Group Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71.
69. McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer's disease. Progr Neuro-Physiopharm Biol Psych 27, 741-749. (Pubitemid 36966754)
70. Wallace JL, Pittman QJ, Cirino G (1995) Nitric-oxidereleasing NSAIDs: A novel class of GI-sparing antiinflammatory drugs, agents. Actions Suppl 46, 121-129.
71. Pontiki EA, Hadjipavlou-Litina DJ (2003) Synthesis, antioxidant and antiinflammatory activity of novel aryl-acetic and aryl-hydroxamic acids. Arzneimittelforschung 53, 780-785. (Pubitemid 37463923)
72. Pontiki E, Hadjipavlou-Litina D (2006) Antioxidant and antiinflammatory activity of aryl-acetic and hydroxamic acids as novel lipoxygenase inhibitors. Med Chem 2, 251-264. (Pubitemid 44083143)
73. Pontiki E, Hadjipavlou-Litina D (2007) Synthesis of phenylsubstituted amides with antioxidant and anti-inflammatory activity as novel lipoxygenase inhibitors. Med Chem 3, 75-86.
74. Xu H, Sweeney D, Wang R, Thinakaran G, LoAC, Sisodia SS, Greengard P, Gandy S (1997) Generation of Alzheimer beta amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci U S A 94, 3748-3752. (Pubitemid 27180444)
75. Thinakaran G, Teplow DB, Siman R, Greengard P, Sisodia SS (1996) Metabolism of the 'Swedish' amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the 'beta-secretase' site occurs in the Golgi apparatus. J Biol Chem 271, 9390-9397.
76. Gniadecki R, Christoffersen N, Wulf HC (2002) Cholesterolrich plasma membrane domains (lipid rafts) in keratinocytes: Importance in the baseline and UVA-induced generation of reactive oxygen species. J Invest Dermatol 118, 582-588. (Pubitemid 34309976)
77. Marchesi E, Rota C, Fann YC, Chignell CF, Mason RP (1999) Photoreduction of the fluorescent dye 2, 7-dichlorofluorescein: A spin trapping and direct electron spin resonance study with implications for oxidative stress measurements. Free Radic Biol Med 26, 148-161. (Pubitemid 29001502)
78. Chignell CF, Sik RH (2003) A photochemical study of cells loaded with 2, 7-dichlorodluorescin: Implications for the detection of reactive oxygen species generated during UVA irradiation. Free Rad Biol Med 34, 1029-1034. (Pubitemid 36398562)
79. Slater TF, Sawyer B, Straeuli U (1963) Studies on succinatetetrazolium peductase systems. III. Points of coupling of four different tetrazolium salts. Biochim Biophys Acta 77, 383-393.
80. Yan JJ, Kim DH, Moon YS, Jung JS, Ahn EM, Baek NI, Song DK (2004) Protection against b-amyloid peptideinduced memory impairment with long-term administration of extract of Angelica gigaw or decursinol in mice. Progr Neuro-Psychopharmacol Biol Psych 28, 25-30.
81. Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 20, 325-330. (Pubitemid 29525418)